Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL.
- These patients also experienced improvements in key metabolic and lipid measures such as HOMA-IR, serum triglycerides and LDL.
- “Miricorilant is highly active in the liver with a unique mechanism of action and holds great promise for the treatment of NASH,” said Naim Alkhouri, MD, FAASLD, Chief Medical Officer of Arizona Liver Health.
- “The combination of liver fat reduction, improvement in metabolic and lipid measures and low adverse event rate is compelling.
- Miricorilant has the potential to be a potent solution for the large patient population with NASH.”